Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks
E_PH_1.4.1,Biotransformation,"- Biotransformation Reactions
- Phase I and Phase II reaction with suitable examples
- Importance of Enzyme Induction and Enzyme Inhibition;- Microsomal Enzyme Induction and Inhibition with examples",True,2,2014-08;2010-02,n=PH-kdtemp&ed=8&vol=0#28,"A 35 year old woman taking combined oral contraceptive pills. She was a diagnosed as a case of tuberculosis and put on isoniazid, rifampicin, pyrazinamide, and ethambutol combination therapy for 2 months followed by isoniazid and rifampicin thrice weekly for 4 months. In the 3rd month of treatement, she failed to have withdrawal bleeding during the gap period of contraceptive cycle. One week later her urinary pregnancy test was found to be positive.",
S_PH_1.1.1,Pharmacogentics,- Two Examples,True,6,2023-02;2021-09;2017-08;2009-02;2008-02;2001-04,n=PH-kdtemp&ed=8&vol=0#75,,
S_PH_1.11.2.1,Sublingual Route of Drug Administration,,True,3,2011-08;2008-08;1997-10,n=PH-kdtemp&ed=8&vol=0#12,,
E_PH_1.11,Routes of Drug Administration,"- Explanation of Each Route
- Examples
- Advantages
- Disadvantages",True,1,2001-04,n=PH-kdtemp&ed=8&vol=0#9,,
S_PH_1.4.2,Bioavailability,,True,4,2020-02;2009-08;2004-08;2001-04,n=PH-kdtemp&ed=8&vol=0#22,,
S_PH_1.11.1,Local Routes Of Drug Administration,,True,1,2010-02,n=PH-kdtemp&ed=8&vol=0#10,,
S_PH_1.3.1,Newer Drug Delivery System,,True,5,2023-02;2013-02;2011-02;2008-02;1994-11,n=PH-tarav&ed=4&vol=0#8,,
S_PH_1.4.3,First Pass Metabolism[Presystemic Elimination],,True,4,2016-08;2007-02;1998-10;1993-01,n=PH-kdtemp&ed=8&vol=0#34,,
S_PH_1.4.4,Biological Half-life[Plasma Half Life],"- Drugs with short half life
- Drugs with long and very short half life",True,6,2023-07;2018-08;2017-02;2005-08;2002-03;1995-11,n=PH-kdtemp&ed=8&vol=0#39,,
S_PH_1.5.2.1,Intracellular Receptors,,True,1,2020-11,n=PH-kdtemp&ed=8&vol=0#60,,
S_PH_1.4.5,Prolongation Of Drug Action,,True,2,2023-07;1996-04,n=PH-kdtemp&ed=8&vol=0#42,,
S_PH_1.5.3,Therapeutic Index,,True,2,2007-08;1996-10,n=PH-kdtemp&ed=8&vol=0#65,,
S_PH_1.5.1.1,Drug Tolerance (Tachyphylaxis),,True,6,2023-02;2022-02;2017-08;2009-02;2002-03;1997-04,n=PH-kdtemp&ed=8&vol=0#80,,
S_PH_1.5.2,Drug Receptor,,True,1,2000-10,n=PH-kdtemp&ed=8&vol=0#48,,
S_PH_1.11.2.2,Transdermal Application Of Drugs,,True,2,2022-02;2000-10,n=PH-kdtemp&ed=8&vol=0#12,,
S_PH_1.4,Pharmacokinetics,,True,1,,n=PH-kdtemp&ed=8&vol=0#15,,
S_PH_1.7.1,Teratogenicity,,True,3,2022-08;2019-02;2001-11,n=PH-kdtemp&ed=8&vol=0#99,,
S_PH_1.4.1.1,Prodrug,,True,1,2004-08,n=PH-kdtemp&ed=8&vol=0#28,,
S_PH_1.5.4,Drug Antagonism,,True,3,2012-02;2005-02;2001-11,n=PH-kdtemp&ed=8&vol=0#67,,
S_PH_1.4.6,Blood Brain Barrier,,True,1,2011-08,n=PH-kdtemp&ed=8&vol=0#24,,
S_PH_1.1.2,Essential Drugs,,True,1,2012-02,n=PH-kdtemp&ed=8&vol=0#6,,
S_PH_1.4.1.2,Microsomal Enzyme Inducers,,True,2,2023-02;2012-02,n=PH-kdtemp&ed=8&vol=0#33,,
S_PH_1.59.1,Fixed Dose Ratio Combination,,True,1,2013-02,n=PH-kdtemp&ed=8&vol=0#72,,
S_PH_1.4.7,Specialized Active Transport Mechanism Across Blological Membrane,,True,1,2013-08,n=PH-kdtemp&ed=8&vol=0#18,,
S_PH_1.6.1,Pharmacovigilance,,True,6,2022-08;2022-03;2021-09;2018-02;2016-02;2013-08,n=PH-kdtemp&ed=8&vol=0#93,,
S_PH_1.11.2.3,Parenteral Route of Drug Administration,,True,1,2019-08,n=PH-kdtemp&ed=8&vol=0#13,,
S_PH_1.7.2,Drugs in Anaphylactic Shock,,True,1,,n=PH-kdtemp&ed=8&vol=0#97,,
S_PH_1.4.1.4,Phase 2 Biotransformation Reactions with Suitable Examples,,True,2,2022-03;2020-02,n=PH-kdtemp&ed=8&vol=0#31,,
S_PH_1.5.4.1,Receptor antagonism drugs,,True,1,2011-08,n=PH-kdtemp&ed=8&vol=0#68,,
S_PH_1.5.1.2,Drug Responses in Elderly,,True,1,2012-08,n=PH-kdtemp&ed=8&vol=0#74,,
E_PH_1.5.1,Factors Modifying Drug Action,"- Definition Drug and Dose
- Various Factors Modifying a Drug's Actions
- Note about Pharmacogenetics",True,2,2015-08;2010-08,n=PH-kdtemp&ed=8&vol=0#73,,
S_PH_1.4.1,Biotransformation,,True,2,2008-08;1999-04,n=PH-kdtemp&ed=8&vol=0#28,,
S_PH_1.64.1,Post Marketing Surveillance During Newer Drug Development (Phase IV Clinical Trial),,True,2,2017-02;1995-11,n=PH-kdtemp&ed=8&vol=0#91,,
S_PH_1.7.3,Iatrogenicity,,True,1,2000-10,n=PH-kdtemp&ed=8&vol=0#101,,
S_PH_1.4.9,Protein Binding of Drugs,- Clinical significance with Examples,True,2,2021-09;2003-10,n=PH-kdtemp&ed=8&vol=0#25,,
S_PH_1.4.1.3,Phase 1 biotransformation reaction with examples,,True,1,2006-08,n=PH-kdtemp&ed=8&vol=0#29,,
S_PH_1.5.3,Drug Synergism,,True,1,2016-02,n=PH-kdtemp&ed=8&vol=0#66,,
S_PH_1.11.2.4,Rectal Route of Administration,- Merits and Demerits,True,1,2023-12,n=PH-kdtemp&ed=8&vol=0#12,,
S_PH_1.1.3,Orphan Drugs,,True,1,2018-08,n=PH-kdtemp&ed=8&vol=0#7,,
S_PH_1.64.2,Phase III Clinical Trial,,True,2,2022-02;2019-02,n=PH-kdtemp&ed=8&vol=0#91,,
S_PH_1.4.8,Zero Order Pharmacokinectics,,True,1,2019-08,n=PH-kdtemp&ed=8&vol=0#38,,
S_PH_1.5.4.2,Physical Antagonism,,True,1,2020-11,n=PH-kdtemp&ed=8&vol=0#67,,
S_PH_1.6.2,Causality Assessment,,True,1,2022-08,n=PH-kdtemp&ed=8&vol=0#93,,
